Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study

Pembrolizumab is a humanized monoclonal antibody that blocks interaction between programmed death receptor-1 (PD-1) and its ligands (PD-L1, PD-L2). Although pembrolizumab is approved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), its role in the management of locally advance...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2020-07, Vol.38 (21), p.2427-2437
Hauptverfasser:	Powell, Steven F, Gold, Kathryn A, Gitau, Mark M, Sumey, Christopher J, Lohr, Michele M, McGraw, Steven C, Nowak, Ryan K, Jensen, Ashley W, Blanchard, Miran J, Fischer, Christopher D, Bykowski, Julie, Ellison, Christie A, Black, Lora J, Thompson, Paul A, Callejas-Valera, Juan L, Lee, John H, Cohen, Ezra E W, Spanos, William C
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - pharmacology Antineoplastic Agents, Immunological - therapeutic use Chemoradiotherapy - methods Female Humans Male Middle Aged ORIGINAL REPORTS Retrospective Studies Squamous Cell Carcinoma of Head and Neck - drug therapy Squamous Cell Carcinoma of Head and Neck - radiotherapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!